The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Generation of Soluble NKG 2 D Ligands: Proteolytic Cleavage, Exosome Secretion and Functional Implications
Open accessAbstract
The activating natural killer group 2 member D (NKG 2 D) receptor is expressed on NK cells, cytotoxic T cells and additional T cell subsets. Ligands for human NKG 2 D comprise two groups of MHC class I‐related molecules, the MHC class I chain‐related proteins A and B (MICA/B) and 6 UL 16‐binding proteins (ULBP 1‐6). While NKG 2 D ligands are absent from most normal cells, expression is induced upon stress and malignant transformation. In fact, most solid tumours and leukaemia/lymphomas constitutively express at least one NKG 2 D ligand and thereby are susceptible to NKG 2 D‐dependent immunosurveillance. However, soluble NKG 2 D ligands are released from tumour cells and can down‐modulate NKG 2 D activation as a means of tumour immune escape. In some tumour entities, levels of soluble NKG 2 D ligands in the serum correlate with tumour progression. NKG 2 D ligands can be proteolytically shed from the cell surface or liberated from the membrane by phospholipase C in the case of glycosylphosphatidylinositol (GPI)‐anchored molecules. Moreover, NKG 2 D ligands can be secreted in exosomal microvesicles together with other tumour‐derived molecules. Depending on the specific tumour/immune cell setting, these various forms of soluble and/or exosome‐bound NKG 2 D ligands can exert multiple effects on NKG 2 D/NKG 2 D ligand interactions. In this review, we focus on the role of various proteases in the shedding of human NKG 2 D ligands from tumour cells and discuss the not completely unanimous reported functional implications of soluble and exosome‐secreted NKG 2 D ligands for immunosurveillance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Innate or adaptive immunity? The example of natural killer cells
Vivier, E., Raulet, D. H., Moretta, A., Caligiuri, M. A., Zitvogel, L., Lanier, L. L., Yokoyama, W. M., & Ugolini, S. (2011) · Science · doi:10.1126/science.1198687 · Cited by 2,824
NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy
Guerra, N., Tan, Y. X., Joncker, N. T., Choy, A., Gallardo, F., Xiong, N., Knoblaugh, S., Cado, D., Greenberg, N. R., & Raulet, D. H. (2008) · Immunity · doi:10.1016/j.immuni.2008.02.016 · Cited by 850
MICA Engagement by Human Vγ2Vδ2 T Cells Enhances Their Antigen-Dependent Effector Function
Das, H., Groh, V., Kuijl, C., Sugita, M., Morita, C. T., Spies, T., & Bukowski, J. F. (2001) · Immunity · doi:10.1016/s1074-7613(01)00168-6 · Cited by 409
McGilvray, R. W., Eagle, R. A., Watson, N. F. S., Al-Attar, A., Ball, G., Jafferji, I., Trowsdale, J., & Durrant, L. G. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0991 · Cited by 196
Cited by
NK cells for cancer immunotherapy
Shimasaki, N., Jain, A., & Campana, D. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0052-1 · Cited by 1,222
Recognition of Tumors by the Innate Immune System and Natural Killer Cells
Marcus, A., Gowen, B. G., Thompson, T. W., Iannello, A., Ardolino, M., Deng, W., Wang, L., Shifrin, N., & Raulet, D. H. (2014) · Advances in Immunology · doi:10.1016/b978-0-12-800267-4.00003-1 · Cited by 394
Ye, S.-B., Li, Z.-L., Luo, D.-H., Huang, B.-J., Chen, Y.-S., Zhang, X.-S., Cui, J., Zeng, Y.-X., & Li, J. (2014) · Oncotarget · doi:10.18632/oncotarget.2118 · Cited by 346
A shed NKG2D ligand that promotes natural killer cell activation and tumor rejection
Deng, W., Gowen, B. G., Zhang, L., Wang, L., Lau, S., Iannello, A., Xu, J., Rovis, T. L., Xiong, N., & Raulet, D. H. (2015) · Science · doi:10.1126/science.1258867 · Cited by 255
NKG2D and Its Ligands: “One for All, All for One”
Zingoni, A., Molfetta, R., Fionda, C., Soriani, A., Paolini, R., Cippitelli, M., Cerboni, C., & Santoni, A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00476 · Cited by 254
Metadata
- Authors
- Chitadze, G., Bhat, J., Lettau, M., Janssen, O., & Kabelitz, D.
- Venue
- Scandinavian Journal of Immunology
- Publisher
- Wiley
- Published
- 2013-07-21
- Volume
- 78
- Issue
- 2
- Pages
- 120-129
- ISSN
- 0300-9475 (ISSN-L)
- 1365-3083
- OpenAlex
- W1963731169
- Cited by
- 186
- References
- 4
- FWCI
- 7.87
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.